Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd6a5dbb2cf703f257b3371e6e8adbca |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-06 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N1-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-582 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N1-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-77 |
filingDate |
2021-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41f9c64989cda104e21442807d4c3632 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9a3138451baad4f69b4dc3fc6b8ec9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f7d6a2318f8b3bbd112c65f312c7116 |
publicationDate |
2021-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-3114536-A1 |
titleOfInvention |
A method for determining likelihood of an inflammatory gastrointestinal tract disease |
abstract |
The present invention relates to method for determining a likelihood of an inflammatory gastrointestinal tract disease. The method comprises diluting a biological sample of a human subject and contacting it with 8-anilinonaphthalene-1-sulfonic acid as modulating agent and further with a reagent, said reagent comprising a peroxidase enzyme and a label selected from a europium chloride and terbium chloride. The sample is incubated and excited, and the time-resolved luminescence signal of the label in the sample is measured. If the luminescence signal is at least 112 % higher than for a control sample from a human subject without of an inflammatory intestine disease, an increased likelihood of an inflammatory intestine disease of the human subject is determined. |
priorityDate |
2020-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |